BIIB Biogen Inc.
Price Chart
Executive Summary
Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary endpoint (dose response on CDR-SB) but showed slowing of cognitive decline in pre-specified analyses and robust tau reduction across doses. Biogen plans to advance to registrational development, creating a mixed outlook for the stock.
Actionable Insight
The mixed CELIA results may cause near-term volatility. Watch for regulatory feedback and details on the registrational trial design. Tau-directed therapy is a new mechanism; initial market reaction could be positive on cognitive signals, but primary endpoint miss tempers enthusiasm.
Key Facts
- Phase 2 CELIA study (n=416) of diranersen (BIIB080) in early Alzheimer's disease did not meet its primary endpoint of dose response on CDR-SB at Week 76.
- Pre-specified analyses showed slowing of clinical decline, particularly at the lowest dose (60 mg every 24 weeks).
- Robust reductions in CSF tau and tau PET across all doses, consistent with Phase 1b data.
- Safety profile generally consistent with prior studies; higher serious adverse events at highest dose.
- Biogen plans to engage regulators and initiate registrational development.
- FDA granted Fast Track designation in 2025.
Financial Impact
No financial data in release. Potential market for tau-targeting Alzheimer's therapy is large, but clinical and regulatory path remains uncertain.
Risk Factors
- Primary endpoint miss may raise regulatory hurdles and require larger confirmatory trial.
- Higher serious adverse events at highest dose could limit dosing or risk-benefit profile.
- Competition from amyloid-targeting therapies and other tau-directed programs.
- Historical calibration for BIIB shows poor win rate on prior reports; market may be skeptical of these data.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $192.62 (−1.02%) |
|
Jun 4, 2026
5d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $192.62 (−1.63%) |
|
Jun 1, 2026
8d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $192.62 (+0.21%) |
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $192.62 (+22.98%) |
|
May 22, 2026
18d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $192.62 (+1.32%) |
|
May 21, 2026
19d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $192.62 (+0.63%) |
|
May 20, 2026
20d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $192.62 (+5.07%) |
|
May 14, 2026
26d ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $192.62 (+7.76%) |
|
May 14, 2026
26d ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $192.62 (+0.71%) |
|
May 14, 2026
26d ago
|
8-K
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $192.62 (+0.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access